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Mutations in theGBA gene that encodes glucocerebrosidase cause the lysosomal storage disorder
Gaucher disease but also increase the risk for Parkinson’s disease. Mazzulli et al. (2011) uncover
a possible mechanism to explain this connection: loss of glucocerebrosidase creates a positive
feedback loop of reduced lysosomal function and a-synuclein accumulation, ultimately leading
to neurodegeneration.Genetics has taught us a great deal about
disorders in which the underlying cause is
complex and, thus, often relegated to the
catch all ‘‘sporadic’’ diseases. However,
the gap between identifying genes and
understanding their pathogenic pathways
remains enormous. In this context, the
new study by Mazzulli et al. (2011) in the
current issue of Cell uncovers a tractable
biochemical relationship between two
complex diseases, the neurodegenera-
tive disorder Parkinson’s disease and
the lysosomal disorder Gaucher disease,
in which lipids accumulate in central
organs.
Parkinson’s disease is characterized by
two pathological features. First, neurons
die in regions of the brain, which control
the normal fluidity of movement. This
leads to the clinical picture of tremor, stiff-
ness, slowness, and difficulties with
posture. Second, proteins and lipids
accumulate into structures, called Lewy
bodies, inside surviving neurons (Gai
et al., 2000). The synaptic protein a-synu-
clein is one key component of Lewy
bodies, and variations in its gene, SNCA,
are associatedwith inherited andsporadic
Parkinson’s disease (Hardy, 2010). When
present in Lewy bodies, a-synuclein is
aggregated; however, it is unclear which
species causes cell death, the aggregated
form or some intermediate in the aggrega-
tion pathway, such as soluble oligomers.
Gaucher disease is anautosomal reces-
sive disorder caused by mutations in
theGBAgene,which encodes the enzyme
glucocerebrosidase (GCase). Parents and
grandparents of patients with Gaucher
disease have unusually high rates of Par-kinson’s disease, suggesting that these
mutations are risk factors for Parkinson’s
disease (Velayati et al., 2010). Although
mutations underlying Gaucher disease
are loss of function, patients with Parkin-
son’s disease always carry one wild-type
GBA allele and thus possess at least
50% of normal enzyme function. Further-
more, there is no obvious correlation
between the type of GBA mutation (i.e.,
completely inactive or one with some
residual enzyme activity) and the risk of
Parkinson’s disease (Velayati et al.,
2010). Thus, the genetic mechanism by
which GBA mutations promote Parkin-
son’s disease is still not clear.
GCase catalyzes the conversion of glu-
cocerebroside to glucose and ceramide
inside the lysosome. One possible link
between GCase function and Parkinson’s
disease risk is a-synuclein. The main
degradation pathway of a-synuclein is
via lysosomal processing, and GCase
interacts with a-synuclein in acidic envi-
ronments, such as the lumen of the lyso-
some (Yap et al., 2011). Interestingly,
a-synuclein has been shown to inhibit
vesicle transport between the endo-
plasmic reticulum (ER) and the Golgi
apparatus, the main trafficking route for
GCase to reach the lysosome. Thus,
increased expression of a-synuclein
should decrease levels of GCase in lyso-
somes. As an aside, mutant a-synuclein
can inhibit chaperone-mediated autoph-
agy, a process by which some substrates
are imported into and degraded by the
lysosome (Cuervo et al., 2004). Therefore,
lysosomal dysfunction could increase
a-synuclein levels, and a-synuclein couldCinhibit lysosomal function in multiple
ways.
Indeed, the central idea in the paper by
Mazzulli et al. is that this exact type of
positive feedback loop occurs in Parkin-
son’s disease patients carrying GBA
mutations. To model the loss of enzyme
function seen in these patients, the
authors decrease the expression of GBA
in mouse neurons to 50% of control
conditions. Over a few days in culture,
the neurons loose lysosomal turnover of
long-lived proteins, including a-synuclein.
The author observe this phenotype in
primary neurons and in neurons reprog-
rammed from induced pluripotent stem
cells (iPSCs), with the latter having both
copies of GBA mutated, as found in
neurons from patients with Gaucher
disease.
The authors then characterize the
formation of a-synuclein oligomers in
cells, in mice, and in brains from people
who had mutations inGBA. Soluble oligo-
mers are found in neuronopathic forms of
Gaucher disease, as well as Parkinson’s
disease patients heterozygous for GBA
mutations. This observation suggests
that the emergence of oligomers is not
correlated with Lewy bodies but rather is
a more fundamental consequence of
GBA mutations. Mazzulli and colleagues
also show that expression of a-synuclein
impacts the trafficking of GCase from
the ER-golgi to the lysosome, indicating
that a-synuclein affects lysosomes
irrespective of the presence of GBA
mutations.
Simplistically, the data by Mazzulli
and colleagues suggest the followingell 146, July 8, 2011 ª2011 Elsevier Inc. 9
Figure 1. A Possible Mechanism Linking Parkinson’s Disease to Gaucher Disease
(A) Under normal conditions, a-synuclein is imported into the lysosome for degradation. The degradative enzyme glucocerebrosidase (GCase) is also imported
into the lysosome after the enzymematures through the ER-Golgi pathway. In pathogenic situations, accumulation of a-synuclein may block ER-Golgi transport,
leading to the loss of GCase in the lysosome. This amplifies the effects by limiting degradation of a-synuclein, causing further accumulation of the protein and
possibly other detrimental effects on the lysosome.
(B) If this series of positive feedback loops (small circles with arrows) continues over time, then a-synuclein levels will tend to increase with age. Presumably, at
a certain point, a-synuclein levels will exceed a pathogenic threshold (arbitrarily indicated by a red line) and be associated with disease.model: a rise in a-synuclein levels through
mutation, response to stress, or neuronal
maturation (Li et al., 2004) inhibits the
normal negative feedback loop of
degradation by the lysosome, leading to
more a-synuclein and more inhibition
(Figure 1A). Then the systemwould transi-
tion from one stable state to a second one
that is self-sustaining, unless another
pathway intervenes to stop it.
Clearly, these are important results and
conclusions for research on Gaucher
disease andParkinson’sdisease. If patho-
genesis is driven by positive feedback that
triggers disease when it rises above
a given threshold (Figure 1B), then we
may now have a simple model that
explains a number of peculiarities of neu-
rodegeneration. First, homeostatic pro-
cesses that keep the feedback loops in
check may fail with time, leading to the
age association observed for neurode-
generation. These models also postulate
that stochastic events, such as random
fluctuations in the levels of a-synuclein,
shouldcontributeas strongly topathogen-
esis as genetic or environmental factors.
Finally, if the process is feedforward,
then it should be possible to intervene in
either portion of thecycle and limit toxicity.
The hypothesis by Mazzulli and
colleagues also leads to a few testable
predictions. For example, removing
a-synuclein from models of Gaucher
disease should limit neurodegeneration.
Equally, raising GCase activity in sporadic
Parkinson’s disease should be beneficial.10 Cell 146, July 8, 2011 ª2011 Elsevier Inc.Either intervention would prevent the
pathogenic effects of the other protein,
and there should be directionality.
Replicating some aspects of these new
findings will be challenging because, as
for many rare neurodegenerative disor-
ders, it will be hard to find autopsied
cases for this purpose. Interestingly,
another recent study, which used dif-
ferent approaches to fractionate proteins
in brain than Mazzulli and colleagues,
examined a-synuclein solubility in
Gaucher brains with and without Lewy
bodies and came to somewhat different
conclusions (Choi et al., 2011). The exper-
iments on mouse and primary cell pre-
sented by Mazzulli et al. should be easier
to replicate, and different strategies for
achieving enzymatic deficiency may
prove informative.
A major question that remains is
whether the acute experiments (i.e.,
days-weeks) presented by Mazzulli and
colleagues extrapolate to a very chronic
(i.e., >50 years) human disease. This is
a challenge for many studies on neurode-
generation; laboratory experiments are
required to examine interventions, but
the real human diseases are dramatically
more complex and longer term. There is
a huge amount of literature demonstrating
that oligomeric assemblies of proteins are
toxic in various models of neurodegener-
ation. However, many of these studies
rely on correlative measures, and the
current literature does not disprove the
alternate hypothesis that higher levels ofmonomeric a-synuclein are causal for
pathogenesis. This is mainly because
tools for removing oligomers, while
keeping monomers, are not well
advanced. It would be fascinating to see
how the disease might respond if one
species could be selectively removed.
Human genetics should also be taken
into account. Common variants around
the SNCA locus are associated with
sporadic Parkinson’s disease, perhaps
due to increased expression of a-synu-
clein (Hardy, 2010). It would be interesting
to determine quantitatively how much
additional risk arises when bothGBA vari-
ants and SNCA risk alleles are present.
The positive feedback loop model
(Figure 1A) suggests that the effect of
the allele combination on lifetime risk
would be more than additive, but that
once a-synuclein protein levels reach the
pathogenic threshold (Figure 1B), then
the increased risk would be minimal.
Levels of a-synuclein are narrowly tuned
in the human brain because triplication
alleles, which are associated only with
a 2-fold increase in protein expression
(Singleton et al., 2003), lead to a very
aggressive form of Parkinson’s disease
(Gwinn et al., 2011). Presumably, once
this threshold is reached, additional risk
would be minimal.
Some of these ideas are more easily
tested than others, but as is often true
for first-rate science, the study byMazzulli
and colleagues leads to several new
avenues that can, and should, be tested
by others. In my opinion, the central
conclusion from this study is the positive
feedback loop between a-synuclein
accumulation and GCase dysfunction;
obtaining data to support or refute this
idea will be key to the progress of under-
standing why GBA mutations influence
the risk of Parkinson’s disease in the
next few years.
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Xist RNA inactivates onemammalian X chromosome (the Xi) by associating with it in cis. The mech-
anism of this interaction is unresolved. Jeon and Lee (2011) now show that YY1 binds both Xist RNA
andDNA, thereby providing amechanism to anchor Xist to the Xi and facilitate X chromosome inac-
tivation.Inactivation of one X chromosome in
female mammals is required to equalize
gene dosage between males and fe-
males. This process is regulated by nu-
merous long noncoding RNAs (lncRNAs)
with Xist paramount among them (Lee,
2009). Initiation of X chromosome inacti-
vation (XCI) requires the expression of
Xist exclusively from the future inactive X
(Xi), where it will ultimately coat the entire
X chromosome and induce chromatin
modifications to silence genes encoded
on the Xi. How the Xist RNA becomes
associated with and coats the future Xi
has remained an enigma. In this issue of
Cell, Jeon and Lee report a clever and
somewhat surprising set of studies indi-
cating that a protein, YY1, associates
with the Xist gene locus and the Xist
RNA; this raises the possibility that YY1has a direct role in bridging the Xist RNA
and the Xi (Jeon and Lee, 2011).
Using differentiated, post-XCI cell lines
(immortalized mouse embryonic fibro-
blasts [MEFs]), the authors set out to
study Xist expression from an inducible
transgene with the goal of elucidating
how Xist RNA becomes tethered to its
chromosome of origin. They tested a
model in which a specific Xist DNA
sequence is required to tether Xist RNA
in cis, possibly serving as the nucleation
site for the spread of Xist RNA along the
future Xi. By introducing an Xist transgene
into the genome of differentiated cells, the
Xist DNA was not exposed to chromatin
modifications arising during develop-
mental programming. RNA FISH and
RT-PCR assays were used to discrimi-
nate between endogenous and trans-genic Xist RNA and measure their relative
expression in female cells. As expected,
upon induction, transgenic Xist RNA was
highly expressed and localized in cis to
the transgene. Surprisingly, in female
transgenic lines, RNA FISH revealed that
the normally abundant Xist RNA associ-
ated with the endogenous Xi was dimin-
ished. Neither Xist instability nor reduced
transcription of endogenous Xist ex-
plained these results. Rather, endoge-
nous Xist RNA was migrating (in trans) to
the transgenic Xist DNA locus. This was
a surprising finding as Xist had never
before been seen to migrate between
chromosomes and so was thought to act
only in cis.
The observation of diffusible Xist pro-
vided a means to dissect further the Xist
DNA and RNA sequences responsibleell 146, July 8, 2011 ª2011 Elsevier Inc. 11
